Lagoda Investment Management L.P. Increases Position in TransMedics Group, Inc. (NASDAQ:TMDX)

Lagoda Investment Management L.P. lifted its holdings in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 16.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 73,860 shares of the company's stock after buying an additional 10,555 shares during the period. TransMedics Group makes up 2.5% of Lagoda Investment Management L.P.'s holdings, making the stock its 13th biggest position. Lagoda Investment Management L.P. owned 0.22% of TransMedics Group worth $4,605,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Clear Creek Financial Management LLC purchased a new position in TransMedics Group in the fourth quarter worth approximately $352,000. Vaughan Nelson Investment Management L.P. lifted its stake in TransMedics Group by 9.9% in the fourth quarter. Vaughan Nelson Investment Management L.P. now owns 361,615 shares of the company's stock worth $22,547,000 after acquiring an additional 32,605 shares during the last quarter. Baillie Gifford & Co. lifted its stake in TransMedics Group by 14.9% in the fourth quarter. Baillie Gifford & Co. now owns 269,836 shares of the company's stock worth $16,824,000 after acquiring an additional 34,947 shares during the last quarter. State of Michigan Retirement System purchased a new position in TransMedics Group in the fourth quarter worth approximately $6,734,000. Finally, Peregrine Capital Management LLC lifted its position in shares of TransMedics Group by 64.0% during the 4th quarter. Peregrine Capital Management LLC now owns 66,140 shares of the company's stock worth $4,124,000 after buying an additional 25,814 shares during the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, Director Edward M. Basile sold 6,000 shares of the business's stock in a transaction on Friday, May 9th. The shares were sold at an average price of $115.63, for a total value of $693,780.00. Following the sale, the director now owns 732 shares of the company's stock, valued at $84,641.16. The trade was a 89.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 7.00% of the stock is currently owned by corporate insiders.

TransMedics Group Price Performance

NASDAQ TMDX traded down $0.23 during trading hours on Friday, reaching $121.58. 966,002 shares of the company's stock were exchanged, compared to its average volume of 1,357,894. The stock has a market cap of $4.11 billion, a PE ratio of 129.34 and a beta of 1.91. TransMedics Group, Inc. has a one year low of $55.00 and a one year high of $177.37. The firm has a fifty day moving average of $83.99 and a 200-day moving average of $75.90. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.29 by $0.41. The business had revenue of $143.54 million for the quarter, compared to the consensus estimate of $123.39 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The firm's revenue was up 48.2% compared to the same quarter last year. During the same quarter last year, the business posted $0.35 EPS. On average, equities research analysts predict that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on TMDX. Canaccord Genuity Group restated a "buy" rating and set a $104.00 price objective on shares of TransMedics Group in a research report on Tuesday, March 11th. Oppenheimer boosted their price objective on shares of TransMedics Group from $125.00 to $130.00 and gave the company an "outperform" rating in a research note on Friday, May 9th. Needham & Company LLC reaffirmed a "hold" rating on shares of TransMedics Group in a research note on Wednesday, April 23rd. Finally, Piper Sandler reaffirmed an "overweight" rating and set a $125.00 price target (up from $105.00) on shares of TransMedics Group in a research note on Friday, May 9th. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, TransMedics Group has a consensus rating of "Moderate Buy" and a consensus price target of $126.70.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.